ObsEva SA, en liquidation is a Switzerland-based company which provides services in the fields of research, development, manufacture, registration, promotion and marketing of biotechnical and pharmaceutical products.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-10-06	US$0.000100	0.00%	11,553
26-10-05	US$0.000100	0.00%	6,375
26-10-02	US$0.000100	0.00%	62,521
26-09-30	US$0.000100	0.00%	500
26-09-29	US$0.000100	0.00%	250

Delayed Quote OTC Markets

More quotes

Market Closed - OTC Markets 15:06:20 2026-10-06 EDT			5-day change	1st Jan Change
0.000100 ^USD	0.00%		0.00%	-

23-04-20	ObsEva to Suspend Reporting With SEC Following Delisting From Nasdaq	MT
23-04-20	ObsEva to Change Central Securities Depositary to SIX SIS; Shares Up 9%	MT

Market Cap	4.1M 3.66M 3.42M 3.11M 5.85M 397M 5.89M 41.08M 16.05M 202M 15.4M 15.06M 649M	P/E 2021	-2.57x	P/E 2022	-0.45x
Enterprise Value	-1.3M -1.16M -1.08M -981K -1.85M -125M -1.86M -12.98M -5.07M -63.75M -4.86M -4.76M -205M	EV / Sales 2021	-	EV / Sales 2022	0.65x
Free-Float	70.16%	Yield 2021 *	-	Yield 2022	-

23-04-20	ObsEva to Suspend Reporting With SEC Following Delisting From Nasdaq	MT
23-04-20	ObsEva to Change Central Securities Depositary to SIX SIS; Shares Up 9%	MT
23-04-11	Insider Buy: Obseva	MT
23-04-05	ObsEva SA announced that it has received CHF 0.344 million in funding	CI
23-03-31	ObsEva SA Reports Earnings Results for the Full Year Ended December 31, 2022	CI
23-03-30	ObsEva SA Auditor Raises 'Going Concern' Doubt	CI
23-03-22	ObsEva SA(OTCPK:OBSV.F) dropped from NASDAQ Composite Index	CI
23-03-15	ObsEva to Delist from Nasdaq, Deregister from US SEC	MT
23-03-13	ObsEva Names New CEO From May, Appoints Interim Chairman	MT
23-03-13	ObsEva Names New Interim Chairman, CEO as Reorganization Continues	MT
23-03-13	ObsEva SA Announces CEO Changes, Effective on or About May 1, 2023	CI
23-03-13	ObsEva SA Announces Executive Changes	CI
23-03-03	Top Premarket Gainers	MT

22-08-30	HC Wainwright Downgrades ObsEva to Neutral from Buy	MT
22-08-01	Canaccord Genuity Downgrades ObsEva to Hold From Buy, Adjusts Price Target to $1 From $12	MT
22-07-29	Cantor Fitzgerald Cuts ObsEva to Neutral From Overweight, Price Target to $1 From $6	MT
22-06-03	Cantor Fitzgerald Starts ObsEva at Overweight With $6 Price Target	MT
22-04-26	Canaccord Genuity Starts ObsEva at Buy With $12 Price Target	MT

ObsEva SA Stock

Stocks

OBSEF

CH1260041939

Biotechnology & Medical Research

Valuation: ObsEva SA

Chart: ObsEva SA

Latest news: ObsEva SA

Analysts' recommendations: ObsEva SA

Press Releases: ObsEva SA

News in other languages: ObsEva SA

Price Extremes

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

23-04-20	ObsEva Announces Change of Central Securities Depositary	GL
23-04-20	ObsEva Announces Change of Central Securities Depositary	GL
23-03-31	ObsEva Files Year End 2022 Financial Statements	GL
23-03-22	OBSEVA SA : Other Events (form 8-K)	AQ
23-03-15	ObsEva : Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange - Form 8-K	PU

23-04-20	Obseva-Aktien erhalten im Zuge von Nasdaq-Dekotierung neue ISIN-Nummer
23-04-06	Bourse Zurich: le SMI maintient ses gains à l'approche de la mi-journée
23-04-06	Bourse Zurich: ouverture en hausse avant le long week-end pascal
23-03-31	Obseva bleibt 2022 tief in den roten Zahlen
23-03-31	Obseva reste profondément en rouge en 2022, doutes sur la suite

1 week	0		0
1 month	0		0
Current year	0		0.01
1 year	0		0.01
3 years	0		0.4
5 years	0		2.92
10 years	0		20.35

Date	Insider	Type	Main position	Quantity	% Market Cap.
4/6/23	Ernest Loumaye	Buy	Chief Executive Officer	4,000,000	3.7138%
2/28/23	Ernest Loumaye	Buy	Chief Executive Officer	4,000,000	3.7138%
2/23/23	William Brown	Free	Chief Executive Officer	250,000	0.2321%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
OBSEVA SA	0.00%	0.00%	0.00%	-99.86%	11.72K
WUXI APPTEC CO., LTD.	+4.16%	+4.16%	+49.37%	+94.17%	74.69B
ARGENX SE	+0.46%	-0.97%	+23.51%	+79.34%	58.81B
LONZA GROUP AG	+0.17%	-1.16%	+3.59%	+34.55%	48.45B
REVOLUTION MEDICINES, INC.	+0.50%	-2.14%	+331.33%	+702.20%	42.84B
IQVIA HOLDINGS INC.	-0.72%	-3.99%	+28.50%	+29.94%	42.79B
BEONE MEDICINES AG	+0.34%	-0.52%	+6.56%	+109.35%	41.25B
CELLTRION, INC.	-0.11%	+1.96%	+9.19%	+52.66%	31.13B
WUXI BIOLOGICS (CAYMAN) INC.	-2.07%	+1.16%	+35.00%	+26.28%	30.28B
BIONTECH SE	-0.50%	-3.10%	-10.19%	-14.35%	24.05B
Average	+0.22%	-0.23%	+47.69%	+101.43%	39.43B
Weighted average by Cap.	+0.69%	-0.54%	+55.87%	+130.20%

	2021	2022
Net sales	-	19.64M 17.55M 16.37M 14.87M 28M 1.9B 28.21M 197M 76.85M 966M 73.72M 72.13M 3.11B
Net income	-58.38M -52.16M -48.66M -44.2M -83.25M -5.65B -83.87M -585M -228M -2.87B -219M -214M -9.23B	-29.88M -26.7M -24.91M -22.62M -42.61M -2.89B -42.93M -299M -117M -1.47B -112M -110M -4.73B
Net Debt	-28.08M -25.09M -23.4M -21.26M -40.04M -2.72B -40.34M -281M -110M -1.38B -105M -103M -4.44B	-5.4M -4.82M -4.5M -4.09M -7.7M -522M -7.75M -54.06M -21.12M -266M -20.26M -19.82M -854M